Literature DB >> 11115469

Elevated levels of soluble adhesion molecules in sera and BAL fluid of individuals infected with human T-cell lymphotropic virus type 1.

M Seki1, Y Higashiyama, J Kadota, H Mukae, K Yanagihara, K Tomono, S Kohno.   

Abstract

STUDY
OBJECTIVE: T-lymphocytic alveolitis and increased levels of interleukin-2 receptor-alpha (CD25)-bearing T cells in the BAL fluid (BALF) of human T-cell lymphotropic virus type 1 (HTLV-1) carriers have been reported. Several chemokines and adhesion molecules may contribute to the accumulation of T lymphocytes in the lungs of HTLV-1 carriers. To clarify the correlation between adhesion molecules and HTLV-1-associated pulmonary disorders, we compared the distribution of T-lymphocyte subsets and soluble adhesion molecules, including soluble intercellular adhesion molecule (sICAM)-1, soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble L-selectin (sL-selectin), soluble E-selectin (sE-selectin), and soluble P-selectin (sP-selectin), in BALF and peripheral blood, between HTLV-1 carriers and noninfected healthy subjects.
DESIGN: Flow cytometric analysis with monoclonal antibodies to cell-surface antigens was used to identify T-lymphocyte subsets in BALF samples from HTLV-1 carriers (n = 13) and noninfected healthy control subjects (n = 10). The levels of various soluble adhesion molecules in serum and in BALF were estimated by enzyme-linked immunosorbent assay.
RESULTS: Higher percentages of CD3+ cells, CD3-expressing human leukocyte antigen-DR antigen, and CD3+CD25+ cells were detected in the BALF of HTLV-1 carriers than in that of noninfected control subjects. The concentrations of sICAM-1, sVCAM-1, sL-selectin, SE- selectin, and sP-selectin in the sera of patients were significantly higher than those in noninfected healthy control subjects. The concentration of sICAM-1 in the BALF of patients was significantly higher than that in noninfected healthy control subjects, and the concentration of sICAM-1 correlated well with the percentage of CD3+CD25+ cells.
CONCLUSION: The concentrations of adhesion molecules in the sera of and sICAM-1 in the BALF of HTLV-1 carriers were significantly higher than those in noninfected individuals, and the concentration of sICAM-1 correlated well with the percentage of CD3+CD25+ cells in BALF. Our results suggest a possible interaction between activated T cells bearing CD25 and soluble adhesion molecules, especially sICAM-1, which may contribute to the pulmonary involvement in HTLV-1 carriers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115469     DOI: 10.1378/chest.118.6.1754

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Bronchoalveolar lymphocytosis correlates with human T lymphotropic virus type I (HTLV-I) proviral DNA load in HTLV-I carriers.

Authors:  S Mori; A Mizoguchi; M Kawabata; H Fukunaga; K Usuku; I Maruyama; M Osame
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

2.  Co-infection by human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS?

Authors:  Eduardo Samo Gudo; Nilesh B Bhatt; Dulce Ramalho Bila; Celina Monteiro Abreu; Amílcar Tanuri; Wilson Savino; Suse Dayse Silva-Barbosa; Ilesh V Jani
Journal:  BMC Infect Dis       Date:  2009-12-22       Impact factor: 3.090

3.  Influence of human T lymphotrophic virus type I on diffuse pan-bronchiolitis.

Authors:  M Yamamoto; W Matsuyama; K Oonakahara; M Watanabe; I Higashimoto; M Kawabata; M Osame; K Arimura
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 4.  Pulmonary complications in human T-cell lymphotropic virus type 1 carriers with Sjögren's syndrome, three case reports and literature review.

Authors:  Hui Yu; Futoshi Higa; Ichiro Yamadori; Satomi Yara; Yasushi Tanimoto; Shusaku Haranaga; Masao Tateyama; Jiro Fujita; Mitsune Tanimoto; Huiping Li
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

5.  Influence of human T lymphotrophic virus type I on cryptogenic fibrosing alveolitis - HTLV-I associated fibrosing alveolitis: proposal of a new clinical entity.

Authors:  W Matsuyama; M Kawabata; A Mizoguchi; F Iwami; J Wakimoto; M Osame
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 6.  Human T-cell leukaemia virus type 1 associated pulmonary disease: clinical and pathological features of an under-recognised complication of HTLV-1 infection.

Authors:  Lloyd Einsiedel; Fabian Chiong; Hubertus Jersmann; Graham P Taylor
Journal:  Retrovirology       Date:  2021-01-06       Impact factor: 4.602

7.  Pulmonary function testing in HTLV-I and HTLV-II infected humans: a cohort study.

Authors:  Edward L Murphy; Helen E Ownby; James W Smith; George Garratty; Sheila T Hutching; Ying Wu; Dannie I Ameti
Journal:  BMC Pulm Med       Date:  2003-07-28       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.